XML 61 R24.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Revenue Revenue
 12 Months Ended
Dec. 31, 2019
Revenue from Contract with Customer [Abstract]  
Revenue from Contract with Customer [Text Block]
NOTE O – REVENUE

We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes in our consolidated statements of operations. The following tables disaggregate our revenue from contracts with customers by business and geographic region (in millions):
 
Year Ended December 31,
 
2019
 
2018
 
2017
Businesses
U.S.
 
OUS
 
Total
 
U.S.
 
OUS
 
Total
 
U.S.
 
OUS
 
Total
Endoscopy
$
1,080

 
$
814

 
$
1,894

 
$
980

 
$
781

 
$
1,762

 
$
894

 
$
724

 
$
1,619

Urology and Pelvic Health
1,005

 
408

 
1,413

 
864

 
381

 
1,245

 
785

 
339

 
1,124

Cardiac Rhythm Management
1,135

 
804

 
1,939

 
1,159

 
792

 
1,951

 
1,135

 
760

 
1,895

Electrophysiology
148

 
180

 
329

 
150

 
161

 
311

 
136

 
142

 
278

Neuromodulation
695

 
178

 
873

 
624

 
155

 
779

 
517

 
118

 
635

Interventional Cardiology
1,293

 
1,522

 
2,816

 
1,154

 
1,436

 
2,590

 
1,122

 
1,297

 
2,419

Peripheral Interventions
741

 
651

 
1,392

 
608

 
579

 
1,187

 
575

 
506

 
1,081

Specialty Pharmaceuticals
70

 
11

 
81

 
n/a

 
n/a

 
n/a

 
n/a

 
n/a

 
n/a

Net Sales
$
6,167

 
$
4,569

 
$
10,735

 
$
5,538

 
$
4,286

 
$
9,823

 
$
5,162

 
$
3,885

 
$
9,048


 
Year Ended December 31,
Geographic Regions
2019
 
2018
 
2017
U.S.
$
6,097

 
$
5,538

 
$
5,162

EMEA (Europe, Middle East and Africa)
2,264

 
2,176

 
1,940

APAC (Asia-Pacific)
1,898

 
1,727

 
1,587

LACA (Latin America and Canada)
395

 
383

 
358

Medical Devices
10,654

 
9,823

 
9,048

U.S.
70

 
n/a

 
n/a

OUS
11

 
n/a

 
n/a

Specialty Pharmaceuticals
81

 
n/a

 
n/a

Net Sales
$
10,735

 
$
9,823

 
$
9,048

 
 
 
 
 
 
Emerging Markets (1)
$
1,252

 
$
1,097

 
$
931

(1)
We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets; effective January 1, 2019, we updated our list of Emerging Market countries. Our current list is comprised of the following countries: Argentina, Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Thailand, Turkey and Vietnam. We have revised prior year amounts to the current year’s presentation.

Contract liabilities are classified within Other current liabilities and Other long-term liabilities on our accompanying consolidated balance sheets. Our deferred revenue balance was $400 million as of December 31, 2019 and $373 million as of December 31, 2018. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. We recognized revenue of $143 million in 2019 that was included in the above December 31, 2018 contract liability balance. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred. Refer to Note A – Significant Accounting Policies for additional information on our accounting policies relating to revenue recognition.